Target intelligence / Profile preview

DNA polymerase subunit gamma-1 (POLG)

Target
POLG
Molecular classification
Enzyme, DNA polymerase (Family A), Mitochondrial protein
01

Overview

DNA polymerase subunit gamma-1 (POLG) is the catalytic subunit of mitochondrial DNA polymerase gamma, the sole DNA polymerase responsible for replication and repair of mitochondrial DNA in human cells. It forms the holoenzyme as a heterotrimer, composed of one POLG catalytic subunit and a homodimer of accessory (beta) subunits, which together ensure efficient and accurate replication of the mitochondrial genome. Mutations in POLG are directly associated with a broad range of mitochondrial diseases, particularly affecting tissues highly dependent on oxidative phosphorylation, such as the brain, muscle, and liver. POLG is also susceptible to inhibition by some antiviral drugs, leading to off-target mitochondrial toxicity. It is a key enzyme in mitochondrial genome maintenance, with both DNA polymerase and 3′–5′ exonuclease (proofreading) activities.

Other names
DNA polymerase gamma catalytic subunitPolymerase (DNA directed), gammaPolymerase (DNA) gamma, catalytic subunitMitochondrial DNA polymerase catalytic subunitPolG, catalytic subunitPolG-alphaPOLG1POLGA
02

Mechanism of action

Inhibition of polymerase activity, leading to impaired mitochondrial DNA replication and depletion (for drugs that target both HIV reverse transcriptase and inadvertently inhibit POLG)

03

Biological functions

Mitochondrial DNA replicationMitochondrial DNA repair
04

Disease associations

Neurodegenerative disease (Alpers-Huttenlocher syndrome, progressive external ophthalmoplegia, SANDO, MNGIE)Mitochondrial disordersOther: drug-induced mitochondrial toxicity
05

Safety considerations

Mitochondrial toxicity leading to myopathy, neuropathy, or liver dysfunction (notably from some antiretroviral drugs)Drug-induced lactic acidosis (as a consequence of mitochondrial dysfunction)Genetic heterogeneity and variable penetrance in disease
06

Interacting drugs

Nucleoside reverse transcriptase inhibitors (NRTIs; e.g., zidovudine, stavudine, didanosine; based on mechanism)

1 more in the full profile.

07

Biomarkers

Mitochondrial DNA copy number (used in assessing mitochondrial toxicities/disorders)Mutations in POLG gene (for diagnosis of associated syndromes)

Beyond the preview

Go deeper on DNA polymerase subunit gamma-1 (POLG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA polymerase subunit gamma-1 (POLG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call